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Abstract
Background: Around about 1970, a gentamicin-loaded poly (methylmethacrylate) (PMMA) bone cement brand
(Refobacin Palacos R) was introduced to control infection in joint arthroplasties. In 2005, this brand was replaced by
two gentamicin-loaded follow-up brands, Refobacin Bone Cement R and Palacos R + G. In addition, another
gentamicin-loaded cement brand, SmartSet GHV, was introduced in Europe in 2003. In the present study, we
investigated differences in gentamicin release and the antibacterial efficacy of the eluent between these four
cement brands.
Methods: 200 μm-wide gaps were made in samples of each cement and filled with buffer in order to measure the
gentamicin release. Release kinetics were related to bone cement powder particle characteristics and wettabilities
of the cement surfaces. Gaps were also inoculated with bacteria isolated from infected prostheses for 24 h and
their survival determined. Gentamicin release and bacterial survival were statistically analysed using the Student’s
t-test.
Results: All three Palacos variants showed equal burst releases but each of the successor Palacos cements showed
significantly higher sustained releases. SmartSet GHV showed a significantly higher burst release, while its sustained
release was comparable with original Palacos. A gentamicin-sensitive bacterium did not survive in the high
gentamicin concentrations in the interfacial gaps, while a gentamicin-resistant strain did, regardless of the type of
cement used. Survival was independent of the level of burst release by the bone cement.
Conclusions: Although marketed as the original gentamicin-loaded Palacos cement, orthopaedic surgeons should
be aware that the successor cements do not appear to have the same release characteristics as the original one.
Overall, high gentamicin concentrations were reached inside our prosthesis-related interfacial gap model. These
concentrations may be expected to effectively decontaminate the prosthesis-related interfacial gap directly after
implantation, provided that these bacteria are sensitive for gentamicin.
Background
Deep infections in a total joint replacement are poten-
tially catastrophic events for patients. Antibiotic-loaded
PMMA bone cements (ALBCs) are used in joint repla-
cement procedures to fix implants, with the antibiotic
acting to reduce the risk of infection. Surgeons have
been mixing antibiotics into bone cement, but mixing
antibiotics intra-operatively into carefully composed
bone cement formulas presents certain risks. For exam-
ple, the surgeon can never be sure that the antibiotic is
evenly distributed throughout the mixture, or that the
mechanical properties of t h ec e m e n tw i l ln o tb ec o m -
promised. Commercially-available ALBC is guaranteed
to be evenly blended, and has been shown to have
higher release rates when compared to manually mixed
cement [1].
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first used combination (formerly commercially available
as Refobacin Palacos R) and surgeons have now used
this bone cement for over 30 years. The production of
Refobacin Palacos R (by: Heraeus GmbH; distributor:
Biomet Merck/Biomet Europe) stopped in 2005 because
of corporate reorganization. Subsequently, the two com-
panies filled this blank with follow-up products: Refoba-
cin Bone Cement R (distributed by Biomet Europe) and
Palacos R + G (distributed by Heraeus GmbH). Essen-
tially, both companies claim that the new cements are
equivalent to their predecessor. In addition, SmartSet
G H V( d i s t r i b u t e db yD e P u yC M W )i sag e n t a m i c i n -
loaded bone cement introduced in Europe in 2003.
There are studies published in which various properties
(mechanical properties, handling characteristics, viscos-
ity, volumetric shrinkage), and gentamicin elution of the
three Palacos variants (Refobacin Palacos R, Refobacin
Bone Cement R, and Palacos R + G) and SmartSet GHV
were compared [2-5]. SmartSet GHV contains 1 g of
active gentamicin, all three Palacos variants contain only
0.5 g of active gentamicin. Some studies, however, have
shown that the amount of antibiotic incorporated does
not necessarily determine the amount of release [6,7].
Moreover, the antibacterial efficacy of an ALBC is not
entirely determined by the kinetics of release of the anti-
biotic [8].
Numerous in vitro studies on antibiotic release from
ALBCs have been published [1,6,7], but a major draw-
back of these studies is that they do not account for a
clinically realistic volume-to-area ratio; that is, the anti-
biotic concentrations reached are much lower than can
be achieved clinically due to release into a too large
fluid volume in relation to the cement area from which
antibiotic is released. Thus, the purpose of the present
in vitro study was to investigate whether there are any
differences between the four gentamicin-loaded cements
in terms of their antibiotic release and antibacterial effi-
cacy in a prosthesis-related interfacial gap model [9,10],
that simulates the interfacial gap that occurs in vivo
between bone cement and the bone or prosthesis [11].
Cement powder properties and the wettability of the
cured cement were determined and related to the
release kinetics of the gentamicin.
Furthermore, the influence of the release of the genta-
micin released on survival of bacteria in specimens of
the cured cements was determined.
Methods
Bone cements
Four commercially-available gentamicin-loaded PMMA
bone cement brands were used in this study: Refobacin
Palacos R (Biomet Merck/Biomet Europe, Germany),
Refobacin Bone Cement R (Biomet Europe, Germany),
Palacos R + G (Heraeus Medical GmbH, Germany), and
SmartSet GHV (DePuy CMW, England).
Characterization of cement powder
The morphology, size and shape of the particles of the
cement powders were determined using a field emission
scanning electron microscope (Type 6301F; JEOL,
Japan). The powder was sputter-coated with gold/palla-
dium (~3 nm) and examination was done at an accelera-
tion voltage of 2.0 kV.
The particle size distribution of the powder was deter-
mined using a laser diffraction apparatus (Sympatec
HELOS; Sympatec Gm Clausthal-Zellerfeld, Germany),
using a RODOS dry powder disperser (at 3.0 bar).
A lens of 200 mm was used and calculations were based
on the Fraunhofer diffraction theory. All data given are
the mean of three measurements.
Wettability of bone cements
To establish the wettability of the four bone cement sur-
faces, advancing type contact angles were measured by
putting 1 μl water droplets on a cured cement specimen.
Water droplets were observed with a video-camera, con-
nected to a contour-monitor for observer independent
readings. Four specimens were analyzed per cement,
putting two droplets on each specimen.
Preparation of the interfacial gap model
The preparation of the bone cements started with mix-
ing the powder with the liquid, according to the manu-
facturer’s instructions. This was performed manually
with a spatula in a ceramic bowl, under atmospheric
pressure and at ambient temperature. At the time spe-
cified for the start of application, as stated in the
respective manuals, the cement was spread over a
polytetrafluoroethylene (PTFE) mould. Prior to this,
the mould was fitted with stainless-steel strips with a
thickness of 200 μm, as described before [9,10]. The
thickness of the strip was chosen on the basis of work
by Wang et al. [11], showing that the boundary layer
between bone cement and bone was 50 to 500 μm
wide along 15% of the interfacial circumference in the
femur of a cadaver pig. This prosthesis-related gap
matters most in implant infection, because it is consid-
ered to be an immuno-incompetent zone [12].
After application of the cement, the mould was com-
pressed between two glass plates, covered with copier
overhead film (Océ, MC 110, The Netherlands) to facili-
tate removal after hardening. The glass plates were
manually compressed up to the time specified for final
hardening, after which they are left in place for 24 h.
The stainless-steel strips were subsequently removed
and the cement blocks were gently punched out of the
mould. This yielded cement blocks with a central gap
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2 and a volume of 6 μl, as
detailed previously [9]. The mean mass of each cement
block was 200 mg. The blocks were macroscopically
examined, and those with visibly entrapped gas bubbles
very close to the surface or deviating weights were
discarded.
Gentamicin release in the interfacial gap model,
maintained at 37°C
The first phase of the experiments, only the gaps in five
sample blocks for each bone cement with 6 μLo fP B S
using a standard pipette. Capillary forces spontaneously
contained the fluid inside the gap. After 5, 15, 30, 60,
120, and 240 min in a humid environment (relative
humidity was approximately 90%), a sample block was
taken out and the gap aspirated using a strip of filtration
paper (Schleicher & Schuell, No. 602 h, Germany). Sub-
sequently the filtration paper was put in 5 mL of phos-
phate buffered saline (PBS) and, after 24 h, an aliquot
was taken out and stored at 4°C for later measurement
of its gentamicin concentration.
In the second phase, the outer surface of fresh sample
blocks for each bone cement was coated with three
layers of a commercially available red nail polish. Each
layer was left to dry for 1 h before application of the
next layer. Three layers of the nail polish fully inhibited
gentamicin elution for at least 1 week. By submersing
the coated sample blocks in a larger fluid volume,
thereby allowing gentamicin to diffuse from the gap into
this larger volume, we simulate the clearance of genta-
micin from the gap between bone and bone cement
toward the serum, as occurring in a clinical situation
[9]. The gaps of these blocks were again filled with 6 μL
of PBS, after which the entire block was submersed in a
bulk volume of 10 mL of PBS (see Figure 1). At 1, 6, 24,
48, 72, and 168 h, an aliquot (500 μL) of the bulk fluid
was taken. Aliquots were stored at 4°C prior to measur-
ing their gentamicin concentration.
Gentamicin concentrations were measured using a
procedure introduced by Sampath and Robinson [13]
and modified by Zhang et al. [14]. Briefly, an o-phtal-
dialdehyde reagent was made and stored for 24 h in a
dark environment. The gentamicin sample, o-phtal-
dialdehyde, and isopropanol (to avoid precipitation of
the products formed) were mixed in equal propor-
tions and stored for 30 min at room temperature.
The o-phtaldialdehyde reacted with the gentamicin
amino groups and chromophoric products were
obtained, whose absorbances were measured at 332
nm using a spectrophotometer (Spectronic® 20
Genesys™;S p e c t r o n i cI n s t r u m e n t s ,R o c h e s t e r ,N Y ,
USA). The gentamicin percentages released, relative
to the total amount incorporated, were calculated for
all cements used.
The gentamicin release experiments were performed
in triplicate and a statistical analysis was performed in
order to compare the release rates of each sample type.
To this end, the Student’s t-test for independent sam-
ples was used. A 95% (p < 0.05, two-tailed) confidence
interval was applied for statistical significance.
Antibacterial efficacy of gentamicin eluent in the
interfacial gap model
For bacterial growth, two bacterial strains were used: a
gentamicin-sensitive CNS 7319 (Coagulase Negative Sta-
phylococci 7319; MIC gentamicin = 0.047 μg/mL) and a
gentamicin-resistant CNS 5147 (MIC gentamicin >256
μg/mL). The MIC of gentamicin was determined by
Figure 1 Schematic presentation of gentamicin release into the
filled gap with the possibility of further diffusion into the bulk
fluid. The outer surface of the sample block was effectively covered
by nail varnish (indicated by the pink color) to prevent gentamicin
elution from other surfaces than the gap.
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strains were clinical isolates retrieved from infected joint
prostheses and cultured from cryo preservative beads
(Protect Technical Service Consultants Ltd., Lancashire,
UK) onto blood agar plates at 37°C in ambient air for
2 4h .O n ec o l o n yf r o mt h i sp l a t ew a su s e dt oc r e a t ea
pre-culture in 10 mL Tryptone Soy Broth (TSB, Oxoid,
UK) under the same incubating conditions, yielding a
mean growth density after 24 h for both bacteria of 4.7
×1 0
8 CFU/mL, as determined byc o u n t i n gt h en u m b e r
of colony forming units (CFU) after growth of serial
dilutions on TSB agar plates. This pre-culture was sub-
sequently diluted in TSB at 1:10, to provide new nutri-
ents, prior to filling the gaps in the bone cement with 6
μL of this dilution. These inoculated bone cement
blocks were incubated for 24 h in a water vapour satu-
rated environment at 37°C before microbiological
evaluation.
After bacterial growth in the gaps, the bone cement
blocks were broken to expose the gap surface and both
sides were scraped with a stainless steel surgical blade
to harvest the bacteria adhering to the biomaterial sur-
face. Complete removal of adhering bacteria was occa-
sionally verified using a confocal laser scanning
microscope (Leica TCS-SP2; Leica Microsystems Heidel-
berg GmbH, Heidelberg, Germany). Broken cement
blocks were stained with live/dead bacterial viability
stain after scraping and examined for adhered bacteria.
As there were no green (living) or red (dead) bacteria
seen to be left on the cement surface, it can be safely
assumed that scraping removed all adhered bacteria.
The blade was wiped with a cotton swab, soaked in 9 g/
L sodium chloride, which was then put in 4.5 mL of 9
g/L sodium chloride, vortexed, and sonicated for 60 s in
a 35 kHz ultrasonic bath (Transsonic TP 690-A, Elma®,
Germany). Serial dilutions were made and poured on
TSB agar plates for overnight incubation at 37°C and
enumeration the next day.
All results were expressed in
10log CFU and experi-
ments were carried out in triplicate with separately cul-
tured strains, unless bacterial growth was fully absent
on the gentamicin-loaded variant in the first two experi-
ments in which case the experiment was only performed
twice. To determine effects of the gentamicin release on
bacterial survival and growth,
10log CFU values for gaps
in gentamicin-loaded bone cements were compared,
employing a two-tailed Student’s t-test for unpaired
samples.
Results
Cement powder characteristics
Each cement powder consists of a mixture of different
components (Figure 2). The larger and prevailing struc-
tures observed in all cement powders are spherical
granules corresponding to pre-polymerized PMMA and
the size of these beads varies between 10 μma n d1 0 0
μm. The remainder of the structures observed are much
smaller and correspond with radio-pacifiers (about
15 w/w% zirconium dioxide) and 2-4 wt% gentamicin
particles. Zirconium dioxide particles are more or less
polyhedral with a size range between 1 μmt o5μm, are
added to facilitate X-ray contrast. A problem associated
with the use of 1-5 μm diameter radio-pacifier particles
is that incomplete dispersion of the particles may result
in the formation of particle agglomerates of 50 μm-
200 μm in diameter (Figure 2). The gentamicin particles
(with diameter of 5 μm-4 0μm) in cured SmartSet
GHV clearly appear as spherical particles (Figure 3),
while the Palacos variants include much larger antibiotic
particles with a more crystalline structure (Figure 3).
The particle distributions of the cement powders are
shown in Figure 4. Two features are noted: (a) the pro-
portion of small-sized PMMA beads (mean diameter, d,
between 5 μma n d4 0μm) in the powder, and (b) the
proportion of large-sized PMMA beads (d ≥ 75 μm) in
the powder (Table 1). All Palacos variants contain large-
sized PMMA beads (portion between 10-15 wt%), while
SmartSet GHV only contained small-sized particles.
Wettability
Water contact angles on the different bone cements ran-
ged between 65 and 70 degrees, with no significant dif-
ferences between the four cements.
Gentamicin release characteristics
In Figure 5, the patterns of release of gentamicin from
the cements into the gap, when only the gap is filled
with fluid, are presented. The initial release rate of
SmartSet GHV cement is much higher than of the other
cements. SmartSet GHV cement rapidly obtained a high
gentamicin release during the first 30 min after the start
of an experiment and demonstrates the highest cumula-
t i v er e l e a s ei nt h ef i r s t4h .T h et o t a lr e l e a s ei n t ot h e
gap after 4 h, expressed relative to the amount of genta-
micin incorporated, is 0.8 ± 0.2%, 0.9 ± 0.3%, 1.0 ±
0.7%, 0.7 ± 0.2% for the Refobacin Palacos R, Refobacin
Bone Cement R, Palacos R + G, and SmartSet GHV,
respectively. The minor differences in relative release
may indicate that the higher initial release of SmartSet
GHV is the result of the higher gentamicin content in
this cement.
The patterns of cumulative gentamicin release from
the cement into the bulk fluid, are shown in Figure 6.
Besides differences in the cumulative amounts of genta-
micin released, differences are also seen in the kinetics
of gentamicin release. The release of gentamicin from
SmartSet GHV and Refobacin Palacos R increases some-
what less after prolonged release than from Palacos R +
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from Refobacin Bone Cement R and Palacos R + G is
significantly more rapid, statistical significant increase (p
< 0.05), than the release of gentamicin from SmartSet
GHV and Refobacin Palacos R. After 1 week 8.6 ± 0.6%,
12.2 ± 0.8%, 12.5 ± 3.6%, 3.6 ± 0.4% of the total genta-
micin content of a sample block was released for the
Refobacin Palacos R, Refobacin Bone Cement R, Palacos
R + G, and SmartSet GHV, respectively.
Antibacterial efficacy of gentamicin eluent
T h em e a nn u m b e r so ft h ec o l o n y - f o r m i n gu n i t sh a r -
vested from the bone cement surfaces constituting the
gap when placed in a water saturated environment, i.e.
when only the gap is filled with fluid, are summarised in
Table 2. Sizeable numbers of bacteria were found on all
bone cements for the gentamicin-resistant strain (mean
10log CFU ranged from 4.3 for Refobacin Palacos R to
4.6 for SmartSet GHV) and the small differences were
not statistically significant (p > 0.05). The gentamicin-
sensitive strain was unable to survive in gaps made in
all four gentamicin-loaded cements (Table 2).
Discussion
The continuing emergence of new commercially-avail-
able brands of ALBCs makes it important to establish
which one will provide the most favourable antibiotic
release, and consequently yields the best antibacterial
efficacy. An in vitro antibiotic release and antibacterial
efficacy study was therefore carried out to compare
SmartSet GHV, the original Palacos bone cement (pre-
viously marketed as Refobacin Palacos R), and its two
follow-up products, Refobacin Bone Cement R and Pala-
cos R + G.
Figure 2 SEM micrographs of the Refobacin Palacos R, Refobacin Bone Cement R, Palacos R + G, and SmartSet GHV powder. The arrow
indicates agglomerates of the smaller radiopacifier particles. Bar denotes 100 μm.
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biphasic manner, with most of the antibiotic being
released in the first hours (burst release), and then con-
tinuing to release at low levels (sustained release). Our
gap measurements only represent the burst release,
because longer time intervals were impracticable due to
evaporation of the very small volume (6 μLo fP B S )
inside the gap, and despite positioning of the experiment
in a humid environment. SmartSet GHV showed a sta-
tistically significantly higher gentamicin release in the
gap after 4 h when compared with the three Palacos
variants. All three Palacos variants appeared to have
similar burst releases. As the burst release is due to the
dissolution of antibiotic particles at the surface, the
amount of antibiotics released from bone cement is pro-
portional to its initial concentration in the powder [15].
This is further corroborated by the small differences in
relative amounts released from the three Palacos
variants.
The bulk fluid volume above the gaps obtains its anti-
biotic concentration from diffusion out of the narrow
gap. The gap, however, contains only very small
amounts of antibiotic (about 20 μg in total, as can be
derived from Figure 5), while total gentamicin amounts
in the bulk fluid are tenfold higher (compare Figure 6).
This implies that our bulk gentamicin measurements
solely represent the sustained release of antibiotic out of
the different cements, but cannot be related to a clini-
cally relevant volume as the gap volume itself. There
was no significant difference in gentamicin release mea-
sured in the bulk between Refobacin Bone Cement R
and Palacos R + G, but Refobacin Palacos R released
significantly less gentamicin. This trend is interesting
because the three cements have almost identical compo-
sitions and both Refobacin Bone Cement R and Palacos
Figure 3 SEM micrographs of the fractured surface of cured
specimens of Palacos R + G and SmartSet GHV bone cement.
Note the difference in gentamicin particle shape, indicated by
arrows.
Figure 4 Powder particle size distributions of the Refobacin
Palacos R, Refobacin Bone Cement R, Palacos R + G, and
SmartSet GHV powder.
Table 1 Portion of small-sized (diameter 5 μm-4 0μm)
and large-sized (diameter >75 μm) PMMA beads
Bone cements small-sized beads
(wt%)
large-sized beads
(wt%)
Refobacin Palacos R 30 ± 0 15 ± 0
Refobacin Bone
Cement R
25 ± 1 10 ± 1
Palacos R + G 40 ± 0 10 ± 0
SmartSet GHV 55 ± 0 0 ± 0
Proportions were determined using the numbers presented in Figure 4, with
± indicating the approximate accuracy of the determination.
Figure 5 Gentamicin concentration as a function of time of
exposure to 6 μL of phosphate-buffered saline in a gap. The
values are expressed as mean of three separate experiments, error
bar denotes the average standard deviation.
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for Refobacin Palacos R. Also, there was less gentamicin
release from SmartSet GHV when compared to Refoba-
cin Bone Cement R and Palacos R + G. This finding
confirms previous results in which it was found that,
over a period of 72 h, there was significantly more gen-
tamicin release from Palacos R + G than from SmartSet
GHV [6]. Ideally, gentamicin-loaded bone cements
should present a high total release with sustained high
concentrations of the antibiotic, especially because ami-
noglycosides, such as gentamicin, have a concentration
dependent antibacterial activity [16]. Sustained high gen-
tamicin release is, therefore, clinically desirable as thera-
peutic effectiveness of gentamicin will not continue
once release rates fall below certain levels, possibly asso-
ciated with the risk of inducing antibiotic resistance.
Sustained release requires the penetration of dissolu-
tion fluids into the interconnecting pores and cracks,
which is dictated by the wettability of the polymer
matrices and by the number and sizes of the pores in the
polymer matrix. The wettability of a polymer matrix can
be determined by measuring the water contact angles. If
the water contact angle on a polymer surface decreases,
it implies that the wetting of the surface is better and
that solvent might penetrate more easily in pores and
holes in the matrix to dissolve the antibiotic particles.
Water contact angles of the four bone cements were
between 65 and 70 degrees, i.e. all cements were equally
hydrophobic, indicating that penetration will be equally
slow for all cements. The differences in release kinetics
observed can therefore only be explained by differences
in the number and size of pores in the cements [17].
Sustained release of antibiotics from ALBCs is largely
influenced by porosity of the cement [17], and an
increased polymer-to-monomer ratio leads to increased
porosity and release of antibiotic from the cement [18].
The polymer-to-monomer ratios of Refobacin Palacos R,
Refobacin Bone Cement R, Palacos R + G and SmartSet
GHV are 1.82, 1.83, 1.83 and 1.75, respectively.
Although these differences are small, the higher amount
of monomer in SmartSet GHV may cause a more closed
matrix, explaining the lower sustained release. More-
over, a more closed matrix of Smartset GHV may be
attributed to the large proportion of small-sized PMMA
beads in its powder as compared to the case for the
three Palacos variants.
In addition, large-sized PMMA beads will maintain
their spherical form in the cured cement and will be
responsible for a less dense matrix than can obtained
with small-sized PMMA beads. Therefore, the PMMA
size distribution will affect the gentamicin release.
SmartSet GHV only contained small-sized particles,
while all Palacos variants also contain large-sized
PMMA beads (between 10% and 15%). Although the
above described differences may appear minor, they
greatly influence the density of the bone cement matrix
and consequently the antibiotic release from it.
Both the dose and the duration of the gentamicin release
are, in large part, strongly influenced by the size and shape
of the antibiotic particles [19]. The gentamicin in Palacos
R + G is coarser than in Refobacin Palacos R which,
according to the manufacturer, stimulates more gentami-
cin release from the former cement [20]. Optimum release
is achieved if the antibiotic is in the form of a crystalline
formulation rather than a fine powder [18]. The dissolu-
tion of large crystalline structures from the surface of
PMMA may be more rapid than that of the fine powder
which may be more closely associated with the polymer.
However, use of large antibiotic particles may compromise
its mechanical strength by increasing porosity. SmartSet
Figure 6 Gentamicin concentration as a function of time of
exposure of a gap to 10 mL of phosphate buffered saline. The
values are expressed as mean of three separate experiments, error
bar denotes the average standard deviation.
Table 2 Clinically isolated staphylococcal strains used in this study with their gentamicin susceptibility and inoculum
size (
10log CFU)
Bacterial strain Gentamicin susceptibility Inoculum size Refobacin Palacos R Palacos R + G Refobacin Bone Cement R SmartSet GHV
CNS 7319 Sensitive 8.1 ± 0.7 - - - -
CNS 5174 Resistant 9.3 ± 0.7 4.3 ± 0.4 4.4 ± 0.8 4.4 ± 0.9 4.6 ± 0.8
Also the mean number of colony forming units (
10log CFU) harvested from gaps prepared in the four commercially available gentamicin-loaded bone cements
are shown. Note that only the gaps were filled with fluid and not the volume above the samples. Results are means from three separate experiments (n = 3) ±
SD, unless no growth.
- = no growth.
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tic particles [21]. These particles diffuse in a controlled
manner from the entire cement matrix with minimal effect
on the mechanical stability of the cement.
The extent to which an antibiotic prevents the forma-
tion of a biofilm is an index of its efficacy. Therefore,
differences in biofilm formation have also been investi-
gated for the four gentamicin-loaded bone cements in
an in vitro simulation model of the prosthesis-related
interfacial gap [10]. Bacterial killing in the gaps occurred
only with the gentamicin-sensitive strain, although the
concentrations of gentamicin found inside the isolated
gaps went up to 4000 μg/ml within 4 h. These concen-
trations may be expected to effectively decontaminate
the prosthesis-related interfacial gap directly after
implantation, provided that the bacteria are sensitive for
gentamicin, but appeared insufficient to kill the genta-
micin-resistant strain. Indeed, the gentamicin concentra-
t i o n sf o u n di n s i d et h ei s o l a t e dg a p sw e r eo n l ya b o u t1 0
times higher than the MIC of the resistant strain deter-
mined by using Etest strips, which ignores the additional
resistance created by the biofilm mode of growth occur-
ring in the gap model. Consequently, all four gentami-
cin-loaded bone cements showed bacterial growth of the
resistant strain inside the isolated gap and there was no
significant difference in bacterial survival despite the sig-
nificant higher burst release seen with SmartSet GHV.
Differences in antimicrobial efficacy might become
apparent if a strain with an MIC close to the observed
gentamicin concentrations was selected. In our case,
these concentrations were probably well above or well
below the required levels to kill the particular strain, for
the sensitive and resistant strain, respectively.
Conclusions
Although marketed as the original Refobacin Palacos R,
orthopaedic surgeons should be aware that the successor
cements (Refobacin Bone Cement R and Palacos R + G)
do not appear to have the same release characteristics
as the original cement. All Palacos variants showed
equal burst releases, but each of the successor cements
showed significantly greater sustained releases. SmartSet
GHV showed a significantly higher burst release, while
its sustained release was comparable with original Pala-
cos. Overall, high gentamicin concentrations were
reached inside our prosthesis-related interfacial gaps.
These concentrations may be expected to effectively
decontaminate the prosthesis-related interfacial gap
directly after implantation, provided that these bacteria
are sensitive for gentamicin, as a gentamicin-sensitive
bacterium did not survive in the interfacial gap over a
time period of 24 h, irrespective of the antibiotic-loaded
bone cement involved. A gentamicin-resistant strain did
survive in the interfacial gaps, regardless of the type of
bone cement used. Survival rates were independent of
the level of burst release by the bone cement.
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